Next Article in Journal
Thiophene-Based Compounds with Potential Anti-Inflammatory Activity
Previous Article in Journal
Dietary Effects of Anthocyanins in Human Health: A Comprehensive Review
Previous Article in Special Issue
Current Status of Baricitinib as a Repurposed Therapy for COVID-19
Perspective

Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection

by 1,2,* and 3,4,5
1
Department of Psychiatry, Hôpital Erasme, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium
2
Research Unit (ULB 266), Hôpital Erasme, Université Libre de Bruxelles (ULB), 1050 Brussels, Belgium
3
Pôle Pharmacie, Service Hospitalo-Universitaire de Pharmacie, CHU de Rennes, 35033 Rennes, France
4
Irset (Institut de Recherche en Santé, Environnement et Travail)-Inserm UMR 1085, University of Rennes, CHU Rennes, INSERM, EHESP, 35000 Rennes, France
5
Laboratoire de Biopharmacie et Pharmacie Clinique, Faculté de Pharmacie, Université de Rennes 1, 35043 Rennes, France
*
Author to whom correspondence should be addressed.
Academic Editors: Jean Jacques Vanden Eynde and Annie Mayence
Pharmaceuticals 2021, 14(7), 691; https://doi.org/10.3390/ph14070691
Received: 30 June 2021 / Revised: 15 July 2021 / Accepted: 16 July 2021 / Published: 18 July 2021
(This article belongs to the Special Issue COVID-19 in Pharmaceuticals)
The SARS-CoV-2 outbreak is characterized by the need of the search for curative drugs for treatment. In this paper, we present an update of knowledge about the interest of the functional inhibitors of acid sphingomyelinase (FIASMAs) in SARS-CoV-2 infection. Forty-nine FIASMAs have been suggested in the treatment of SARS-CoV-2 infection using in silico, in vitro or in vivo studies. Further studies using large-sized, randomized and double-blinded controlled clinical trials are needed to evaluate FIASMAs in SARS-CoV-2 infection as off-label therapy. View Full-Text
Keywords: functional inhibitors of acid sphingomyelinase (FIASMAs); acid sphingomyelinase; COVID-19; SARS-CoV-2; mortality functional inhibitors of acid sphingomyelinase (FIASMAs); acid sphingomyelinase; COVID-19; SARS-CoV-2; mortality
MDPI and ACS Style

Loas, G.; Le Corre, P. Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection. Pharmaceuticals 2021, 14, 691. https://doi.org/10.3390/ph14070691

AMA Style

Loas G, Le Corre P. Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection. Pharmaceuticals. 2021; 14(7):691. https://doi.org/10.3390/ph14070691

Chicago/Turabian Style

Loas, Gwenolé, and Pascal Le Corre. 2021. "Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection" Pharmaceuticals 14, no. 7: 691. https://doi.org/10.3390/ph14070691

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop